Items where authors include "Grimm, S."
Up a levelArticle
Dickson, R., Boland, A., Duarte, R. orcid.org/0000-0001-6485-7415 et al. (16 more authors) (2018) EMA and NICE appraisal processes for cancer drugs: Current status and uncertainties. Applied Health Economics and Health Policy, 16 (4). pp. 429-432. ISSN 1175-5652
Hernandez Alava, M., Wailoo, A. orcid.org/0000-0002-9324-1617, Grimm, S. et al. (7 more authors) (2018) EQ-5D-5L versus EQ-5D-3L: the impact on cost-effectiveness in the United Kingdom. Value in Health, 21 (1). pp. 49-56. ISSN 1098-3015
Tappenden, P. orcid.org/0000-0001-6612-2332, Carroll, C. orcid.org/0000-0002-6361-6182, Stevens, J.W. orcid.org/0000-0002-9867-7209 et al. (7 more authors) (2017) Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35 (8). pp. 805-815. ISSN 1170-7690
Monograph
Hernandez Alava, M., Wailoo, A.J. orcid.org/0000-0002-9324-1617, Grimm, S. et al. (7 more authors) (2017) EQ-5D-5L versus 3L: the impact on cost-effectiveness. Report. ScHARR HEDS Discussion Papers . School of Health and Related Research , University of Sheffield.